1. Introduction {#sec1}
===============

In the pathogenesis of mood disorders, including major depressive disorder (MDD) and postpartum depression (PPD), both neuroinflammation and glutamate-mediated excitotoxicity mechanisms (neuronal death through glutamate-based over-activated stimulation) have been suggested to play a key role ([@bib51]; [@bib55]; [@bib73]).

Neurosteroids, and specifically allopregnanolone and its isomer pregnanolone, act as endogenous potent, positive, allosteric modulators of the action of γ-aminobutyric acid (GABA) at GABA type A (GABA~A~) receptors ([@bib118]; [@bib85]; [@bib114]). In addition, sulfated forms of these neurosteroids (e.g., pregnanolone sulfate) influence glutamatergic activity by inhibiting tonic *N*-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission, thereby providing neuroprotection ([@bib152]; [@bib146]). Alterations in GABAergic/glutamatergic system may play a pivotal role in the molecular mechanisms underlying PPD ([@bib153]). Interestingly, allopregnanolone reduces calcium influx through the activation of GABA~A~ receptors expressed on cerebrocortical nerve terminals leading to decreased glutamate release and glial activation, supporting neuroprotective effects ([@bib27]; [@bib102]; [@bib71]). Moreover, evidence showed allopregnanolone inhibits the L-type calcium channel activation-evoked glutamate release in the medial prefrontal cortex ([@bib61]).

Neuroactive steroids can be synthesized peripherally from steroid hormone precursors, such as progesterone, or can be synthesized *de novo* in the brain starting from the conversion of cholesterol to pregnenolone in glial cells ([Fig. 1](#fig1){ref-type="fig"}). Pregnenolone, which is taken up by neurons can be further metabolized to progesterone and by the rate-limiting step enzymes, 5α-reductase Type I (5α-RI) and 3α-hydroxysteroid dehydrogenase (3α-HSD) to allopregnanolone ([@bib4], [@bib3]; [@bib93]; reviewed in [@bib116]). Locally produced allopregnanolone is responsible for the fine-tuning of GABA~A~ receptors in corticolimbic glutamatergic neurons ([@bib114]), a mechanism that has been linked with improvement of behavioral dysfunction ([@bib4]; [@bib116]). At this level, allopregnanolone may conceivably dampen neuroinflammatory processes following activation of glial-type GABA~A~ receptors. Recent evidence shows allopregnanolone, following activation of α2-containing GABA~A~ receptors and subsequent inhibition of toll-like receptor 4, can regulate the immune response by inhibiting proinflammatory processes ([Fig. 1](#fig1){ref-type="fig"}) ([@bib102]; [@bib75]; [@bib13]).Fig. 1**A**. Schematic representation of the relationship between the GABAergic neurosteroid, allopregnanolone, microglial activation and PPAR-α stimulation in postpartum depression (PPD). Immediately after delivery and during the first weeks of the postpartum period, the dramatic drop in circulating progesterone leads to decreased levels of allopregnanolone, which is synthesized from peripherally-derived progesterone by glutamatergic neurons, including pyramidal neurons of the frontal cortex, granular cells of the dentate gyrus and CA1-3 pyramidal neurons in the hippocampus, and pyramidal-like neurons of the basolateral amygdala both in rodent and human brain ([@bib3], [@bib5]; reviewed in [@bib116]). Allopregnanolone plays a central neuromodulatory role in facilitating the action of GABA at GABA~A~ receptors ([@bib85]) and endogenously produced allopregnanolone plays a neurophysiological role in the fine-tuning of the GABA~A~ receptors to GABAmimetics, positive allosteric modulators, and GABA agonists ([@bib114]). By this mechanism, allopregnanolone also regulates emotional behavior and stress-responses. Prolonged stress in animal models results in decreased corticolimbic allopregnanolone levels, which is associated with behavioral dysfunction, including elevated aggressiveness, anxiety-like and depressive-like behavior, and exaggerated fear responses and impaired contextual fear extinction ([@bib115], [@bib116]; [@bib166]; [@bib82], [@bib83]). Low levels of allopregnanolone and symptoms of depression and PTSD have been observed in several clinical studies ([@bib148]; [@bib125]; [@bib121], [@bib122]; [@bib5]; [@bib169]). These neurosteroid deficits result in alterations of GABA and glutamate neurotransmission and in changes in GABA~A~ receptor sensitivity (reviewed by [@bib112]) causing a GABAergic/glutamatergic imbalance. Moreover, decreased allopregnanolone levels in the postpartum period is associated with increased inflammation likely by activated microglia, which releases pro-inflammatory biomarkers, such as IL-1, IL-6 and TNF-α via the NFκB pathway that is also regulated by PPAR. Another mechanism involves the toll-like receptor 4 (TLR4), which, once activated by different triggers such as lipopolysaccharide (LPS), pathogen-associated molecular patterns (PAMPs), alcohol, stress or decreased levels of pregnenolone, forms a complex with intracellular co-activators, such as TIR Domain-Containing Adaptor Protein (TIRAP) and TRIF-related Adaptor Molecule (TRAM) to initiate a pro-inflammatory cascade that leads to NFκB activation and pro-inflammatory cytokines release ([@bib75]). Low levels of allopregnanolone lead to increased calcium channel activity in activated nerve terminals and increased release of glutamate that facilitates excitotoxicity mechanisms ([@bib61]). Unhealthy diets, including high fatty diets or alcohol abuse play deleterious effects on PPAR function that fails to regulate pro-inflammatory processes and greatly contribute to the neuroinflammation mechanisms underlying the pathogenesis of major depression and, possibly, PPD ([@bib56]; [@bib103]). Furthermore, neuroinflammation-associated release of glutamate from activated microglia worsens the neurodegenerative process found in mood disorders. **B**. A schematic representation of the regulatory effects of PPARs following its activation by micronutrients found in functional food that show the ability to bind to PPAR-α. PPAR-α activation by its endogenous modulator, PEA results in enhancement of allopregnanolone biosynthesis, by upregulating the expression of neurosteroidogenic enzymes and proteins, including StAR, P450~ssc~, that facilitate the conversion of cholesterol into pregnenolone, the precursor of all neurosteroids. Pregnenolone is then taken up by glutamatergic neurons and further converted into progesterone and allopregnanolone by the rate-limiting step enzymes, 5α-reductase type I (5α-RI) and 3α-hydroxysteroid dehydrogenase (3α-HSD) in several corticolimbic areas ([@bib83]). In this scenario, restored allopregnanolone binding at GABA~A~ receptors that are expressed in microglia ([@bib4], [@bib3]; [@bib71]), dampens inflammatory processes by an effect mediated through inhibition of TLR4 that results in the subsequent repression of NFκB signaling cascade ([@bib138]; [@bib71]; [@bib102]). Altogether, these actions lead to downregulation in the release of pro-inflammatory cytokines, such as TNF-α and IL-6 and attenuate neurotoxicity. Similar results are observed by administering a diet with functional foods rich in bioactive micronutrients, such as fatty acids, flavonoids, minerals, and vitamins, which represent a non-pharmacological strategy to potentiate PPAR expression and function. PPAR-activation in glia engages neuronal allopregnanolone biosynthesis to regulate inhibition of inflammatory mechanisms, which are ultimately mediated by potentiation of glia GABAergic neurotransmission. At the same time, increased allopregnanolone levels in neurons may stimulate brain derived neurotropic factor (BDNF) and exert important neuroprotective functions ([@bib101]; [@bib7]). We suggest that healthy diets enriched in micronutrients that are PPAR-agonists by enhancing the PPAR-allopregnanolone axis and decreasing inflammation may offer an alternative strategy to pharmacological treatments to prevent and safely treat mood disorders, including PPD.Fig. 1

The recent US Food and Drug Administration (FDA)-approval of the allopregnanolone-based compound, brexanolone, commercially called Zulresso™ for PPD treatment represents an exciting breakthrough for PPD management and opens the field of translational psychiatry to a new generation of neurosteroid-based therapeutics ([@bib70]). These novel agents are characterized by a rapid and long-lasting pharmacological effect after a short-course treatment (reviewed in [@bib164]; [@bib95]). Before brexanolone approval, PPD was mainly treated with psychotherapy for mild-to-moderate cases and selective serotonin reuptake inhibitor (SSRI) antidepressants for the management of severe cases, which are associated with low efficacy and significant side effects (reviewed in [@bib10], and [@bib111]; [@bib60]; [@bib136]). Most importantly, the pharmacological effects of SSRIs only appear after several weeks, which leaves few options for the management of severe PPD. Often, mothers who present suicidal ideations and negative thoughts against self and the baby need to be hospitalized during the lag of time between the start of SSRI treatment and the onset of the beneficial pharmacological effects. This often results in high hospitalization costs and management problems for babies and families ([@bib37]).

Indeed, PPD, whose prevalence is estimated between 10% and 15%, is a mild-to-severe psychiatric condition characterized by the presence of depressed mood, anxiety, sleep disorder, cognitive dysfunction and emotional liability that may begin during pregnancy and/or after birth and lasting for several weeks or months after delivery. According to a Center for Disease Control (CDC) study, 1 in 9 women experience symptoms of PPD and prevalence can be as high as 1 in 5 women ([@bib68]; [@bib135]). Risk factors include history of depressive symptoms, neurotic personality traits, lower social support, lower socioeconomic status, obstetric complications, and major life negative events, trauma and/or stressors during pregnancy ([@bib58]; [@bib120]). If left untreated, PPD may lead to serious health consequences, including child psychological development dysfunction and suicidal behaviors. In addition, women with PPD have higher risk for alcohol abuse compared with women who were neither pregnant nor postpartum ([@bib28]) and alcohol intake has also been associated with peripheral inflammation and neuroinflammation ([@bib103]). In addition, recent evidence suggests that an unhealthy dietary pattern increases the risk of systemic low-grade inflammation and neuroinflammation associated with PPD ([@bib42]; [@bib104]; [@bib150]; [@bib23]; [@bib134]; [@bib141]; [@bib140]; [@bib94]; [@bib127]; [@bib117]).

Brexanolone, despite its proven high efficacy, showed adverse effects such as headache, dizziness, somnolence, and, in some cases, excessive sedation, which may complicate the safety of its use ([@bib70]). Developing alternative neurosteroid-based interventions may improve PDD management more safely.

In this review, we will focus on the role of allopregnanolone in the inflammatory response that may play a relevant role for the onset of depression, as well as the role of functional food-containing bioactive compounds, that show anti-inflammatory effects and may potentially benefit the management of perinatal depression.

New findings show that peroxisome-proliferator activated receptor (PPAR)-α, a ligand-activated transcription factor, which is widely distributed in the mammalian central nervous system (CNS), exhibits anti-inflammatory effects (reviewed by [@bib22]). Together with PPAR-γ, PPAR-α is deeply involved in several physiological and pathological conditions, including regulation of mitochondrial and proteasomal function, neuroinflammation, oxidative stress and neurodegeneration, which are considered key pathogenetic mechanisms involved in stress-related disorders, including anxiety and depression (discussed in [@bib83]; [@bib43]; [@bib2]; [@bib35]). Intriguingly, PPAR mediates anti-inflammatory responses under several pathophysiological conditions and can stimulate biosynthesis of neurosteroids, such as allopregnanolone, with documented anti-inflammatory actions and role in improving mood symptoms, which suggests that the *PPAR-neurosteroid axis* may have a pivotal function in the modulation of mood by regulating inflammatory processes. Hence, a specific focus of this article is devoted on the role of PPAR-α in inflammation while we discuss whether its regulation by functional food-containing active micronutrients, by enhancing allopregnanolone biosynthesis, may benefit prevention and treatment of psychiatric disorders, and specifically PPD.

2. PPAR and inflammation: A role for neurosteroids {#sec2}
==================================================

Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) activation and production of proinflammatory cytokines, such as TNF-α, IL-1β and IL-6, prostaglandins, nitric oxide (NO) and reactive oxygen species (ROS) is regarded as a leading mechanism for local and systemic inflammation. PPAR-α and PPAR-γ are widely distributed in several mammalian organs and tissues and in several areas of the CNS. They mediate several physiological and pathological processes, such as neuroinflammation, regulation of mitochondrial and proteasomal dysfunction, oxidative stress, neurodegeneration, and neuronal differentiation ([@bib98]; [@bib48]).

PPAR-γ is highly expressed in adipocytes and its synthetic agonists have been initially studied as insulin-sensitizing drugs for type-2 diabetes and metabolic syndrome treatment ([@bib21]; [@bib96]). PPAR-γ is also expressed in microglia and astrocytes and plays a major anti-inflammatory role and it is investigated as molecular target for different neurodegenerative diseases, such as brain damage, cerebral ischemia, Parkinson\'s and Alzheimer\'s diseases ([@bib32]; [@bib25]). Its activation, induced by the natural ligand 15-deoxy-d12,14-prostaglandin J2 (15dPGJ2) or synthetic agonists (i.e., pioglitazone), results in a decrease in proinflammatory cytokine production as well as cyclooxygenase-2 (COX-2) through the inhibition of NFκB signaling pathway ([@bib65]; [@bib41]; [@bib30]). In brain, PPAR-γ is involved in the regulation of inflammatory-related gene expression on activated microglia, through which it mitigates neuroinflammatory processes under neuronal insults ([@bib151]). Thus, PPAR-γ, together with PPAR-α, is a suitable pharmacological target to treat inflammatory-derived neuropsychiatric conditions, including MDD and PPD.

Intriguingly, PPAR-α activation stimulates the biosynthesis of allopregnanolone that in addition to elevating mood, has also been associated with an anti-inflammatory effect. Indeed, allopregnanolone binds at GABA~A~ receptors expressed both on microglia and astrocytes and in glutamatergic pyramidal neurons ([@bib3], [@bib4]; [@bib71]), and it mediates anti-inflmmatory effects through blocking toll-like receptor 4 ([@bib13]; [@bib138]; [@bib71]). This results in NFκB inhibition (reviewed in [@bib147] and depicted in [Fig. 1](#fig1){ref-type="fig"}). Allopregnanolone\'s binding at GABA~A~ receptors on monocytoid cells leads to diminished production of inflammatory mediators by these cells ([@bib102]). Further, GABA suppresses astrocytes and microglia inflammatory responses to lipopolysaccharide (LPS) and INF-γ by inhibiting the NFκB activation pathway and P38 MAP kinase ([@bib71]). This process leads to a decreased release of pro-inflammatory cytokines, such as TNF-α and IL-6 and results in an attenuation of neurotoxicity *in vitro* ([@bib71]). Interesting, similar anti-inflammatory effects were observed following the administration of the GABA~A~ receptor agonist, muscimol and the GABA~B~ receptor agonist, baclofen, suggesting the direct role of both types of GABA receptors in reducing neuroinflammation. Interestingly, GABA~A~ receptors are also expressed in macrophages and lymphocytes T cells and their activation produces anti-inflammatory effects ([@bib124]; [@bib18]). In addition, neuroinflammation-associated release of glutamate from activated microglia has been implicated in the progression of neurodegenerative diseases, including Alzheimer\'s and Parkinson\'s disease and recent studies have shown that PPARs can modulate neurotoxicity by inhibiting glutamate release in LPS-activated microglia ([@bib72]).

This evidence collectively supports the hypothesis of a GABAergic/glutamatergic neurotransmission dysregulation as potential molecular mechanism underlying neuroinflammatory processes, whereby the PPAR family and neurosteroid biosynthesis may play a pivotal role (see [Fig. 1](#fig1){ref-type="fig"}). Indeed, recent evidence suggests that neurosteroids regulate neurodegeneration and neuroinflammation supporting neuronal survival either through a direct effect on neurons and/or by decreasing neuroinflammatory responses of microglia and astrocytes ([@bib59]; [@bib11]). *In vitro* and *in vivo* studies show that 17β-estradiol, progesterone, and allopregnanolone reduce microglial-mediated inflammation ([@bib159]).

Hence, an intriguing molecular player that might link inflammation and neurosteroids is represented by PPAR that has been implicated in the pathology of numerous diseases, such as diabetes, stroke, cancer, obesity and even mood disorders ([@bib142]; [@bib80]; [@bib30]; [@bib147]).

3. PPAR role in psychiatric disorders and behavioral regulation {#sec3}
===============================================================

PPAR-α and PPAR-γ exert functions, including glucose and lipid metabolism regulation, anti-inflammatory and oxidative stress inhibition, via a direct inhibition of NFκB signaling ([@bib66]; [@bib126]; [@bib88]). Moreover, PPAR-γ mediates intestinal anti-inflammatory effects, decreases oxidative stress in brain and increases insulin sensitization ([@bib88]). PPARs are key molecular regulators of cell metabolism, energy homeostasis, cellular development, and differentiation; thus, their ligands find several clinical applications, such as hyperlipidemia and hypertriglyceridemia in combination with statins, type-2 diabetes mellitus, metabolic syndrome and non-alcoholic fatty liver disease ([@bib105]; [@bib21]; [@bib30]).

PPAR-α endogenous modulators include palmitoylethanolamide (PEA), oleoylethanolamine (OEA) and stearoylethanolamide (SEA). Specifically, PEA, which was discovered by the Italian Nobel Prize laureate Rita Levi Montalcini in the 90s, is an endogenously synthesized lipid with well described neuroprotective and anti-inflammatory properties ([@bib74]). PEA may play a relevant role in stress-related disorders, including depression and post-traumatic stress disorder (PTSD) ([@bib57]). Indeed, the levels of PEA, OEA and SEA are decreased in PTSD patients ([@bib157]). Both synthetic agonists of PPAR-α and PPAR-γ have been investigated in clinical trials for their ability to improve depression symptoms (reviewed by [@bib147]; [@bib30]). A recent clinical trial investigated the role of PEA as add-on therapy for depression showing symptoms improvement in patients with major depressive disorder treated with citalopram ([@bib52]). Selective PPAR-γ agonists, rosiglitazone and pioglitazone were originally approved by the FDA for diabetes treatment. These compounds also reduce the response to chronic stress and have been studied in a number of clinical trials that evaluated their efficacy in improving depression symptoms (reviewed by [@bib31]; [@bib147]). A combined therapy of pioglitazone with the SSRI antidepressant, citalopram, showed a higher pharmacological response and remission rate, and rapid onset compared to citalopram alone ([@bib133]). In another study, a 12-week pioglitazone administration induced antidepressant effects in patients with comorbid insulin resistance, supporting a link between depression and metabolic dysregulation ([@bib78]).

This evidence suggests that for both PPAR-α and γ, in addition to their anti-cholesterol and anti-diabetic effects, an unforeseen potential therapeutic profile is emerging in the treatment of mood disorders.

4. Functional foods: role in inflammation and PPD {#sec4}
=================================================

*Functional food* is defined as "natural or processed food that contain known or unknown biologically-active compounds; which, in defined, effective, and non-toxic amounts, provide a clinically proven and documented health benefit for the prevention, management, or treatment of chronic disease" ([@bib40]; [@bib89]). A growing body of evidence suggests that many functional foods can modulate inflammation both acutely and chronically through their bioactive compounds and ultimately improve stress-related mood disorders ([@bib6]; [@bib54]; [@bib139]). In fact, diet represents a major modifiable risk factor that modulate the immune system reactivity and a suitable strategy to fight against systemic low-grade inflammation, which is now strongly considered to be involved in the pathogenesis of several chronic diseases, including cardiovascular disease, obesity, diabetes, autoimmune diseases, neurodegenerative diseases, and mood disorders ([@bib77]; [@bib17]; [@bib33]).

Bioactive compounds, such as flavonoids, essential fatty acids, minerals, vitamins, and phytonutrients are essential for overall health and to prevent, manage or treat chronic diseases, including metabolic disorders, diabetes, cardiovascular diseases and hypertension, or pathologies affecting the CNS, including mood disorders ([@bib137]; [@bib161]; [@bib108]; [@bib99]). Increasing evidence indicates that neuroinflammation represents a key biological component in the pathogenesis of psychiatric disorders ([@bib23]; [@bib16]; [@bib84]). Based on the role of inflammation in depressive disorders, including PPD ([@bib106]), as well as the finding from recent clinical studies that have evaluated the efficacy of changes in diet in improving depressive symptoms ([@bib97]), we propose that integrating PPD management with functional foods rich in anti-inflammatory micronutrients might represent an innovative strategy for improving the overall clinical outcome.

PPD shares the same diagnostic criteria as MDD, although the cause of PPD remains more obscure. As in MDD, a combination of environmental and biological factors may occur, including family history, stressful events, unhealthy diet and genetic risk factors ([@bib106]). Moreover, in PPD, a rapid drop in progesterone levels after delivery is considered one of the major risk factors ([@bib132]). Attenuating this dramatic hormonal change might be helpful to avoid severe clinical consequences. Nutrition plays a biological role in depression, especially during pregnancy and lactation during which micronutrients, such as vitamins, minerals, essential fatty acids, and antioxidants become depleted and may play a role in the development of perinatal depression. Some of these nutrients are essential fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), vitamin D, B-vitamins (specifically B6, B9, B12), and trace minerals (like zinc, iron, and selenium) ([@bib8]; [@bib131]).

Omega-3 fatty acids have well-known anti-inflammatory and anti-allergic activity, predominantly through the inhibition of excessive immune responses. EPA- and DHA-derived resolvins and protectins actively ameliorate a pro-inflammatory condition. Polyunsaturated fatty acids (PUFAs) are highly concentrated in neural phospholipids and are important components of the neuronal cell membrane and play a pivotal role in enhancing synaptic plasticity and neuronal communication ([@bib107]). Resolvins and protectins belong to the class of PUFA metabolites, which exert anti-inflammatory activity that regulate the synthesis and release of pro-inflammatory mediators ([@bib64]). DHA and EPA exert different functions, such as maintaining cell-membrane fluidity, inhibiting inflammatory processes by decreasing secretion of proinflammatory cytokines. Foods rich in omega-3 PUFAs are walnuts, sunflower seeds, flax seeds and oil and fatty fish, such as salmon. A recent meta-analysis conducted by [@bib79] suggests a potential role of PUFAs for perinatal depression treatment ([@bib79]). Previous studies have reported controversial results on the beneficial effects of omega-3 fatty acids for perinatal depression treatment in part due to flaws in study design ([@bib49]; [@bib123]). However, a randomized, double-blind, placebo-controlled trial showed that omega-3 improved depressive symptoms ([@bib143]).

The main anti-inflammatory properties of flavonoids include suppressing release of cytokines, such as IL-1β and TNF-α, from activated microglia ([Fig. 1](#fig1){ref-type="fig"}). They may also affect inducible NO synthase regulation and inhibit the activation of NADPH oxidase, and down-regulate the activity of pro-inflammatory transcription factors, such as NFκB, that play a key role in the intestinal inflammatory response ([@bib12]). Green tea, broccoli, onions, and berries are enriched in phytonutrients, such as carotenoids, ellagic acid, flavonoids, resveratrol, glucosinolates, and phytoestrogens that help fighting oxidation and inflammation. Naringenin, quercetin, hydrocaffeic acid, procyanidins, and anthocyanidins ([Table 1](#tbl1){ref-type="table"}) belong to the class of flavonoids and exert anti-inflammatory effects *in vivo* and *in vitro* by inhibiting the expression of iNOS, ICAM-1, MCP-1, COX-2, TNF-α, IL-1β and IL-6 expression ([@bib29]; [@bib53]; discussed in [@bib90]).Table 1Functional Foods rich in micronutrients that activate PPAR-α and PPAR-γ and induce pharmacological effects.Table 1PhytochemicalBioactive CompoundFood SourcePhysiological effectsReferencesFlavonoidsFlavonols*Kaempferol, Myricetin, Quercetin*Berries, kale, grapes, spinach, bell peppers, cocoa, broccoli, sweet potatoes, tomatoes, capersAnti-carcinogenic, anti-inflammatory. antioxidant and antiviral activities. mitigation of microglia-mediated neuroinflammation[@bib154]; [@bib21]; [@bib99]; [@bib156].Flavanones*Hesperetin, Naringenin*Citrus fruits (lemons and oranges), grapesAntioxidant, anti-inflammatoryFlavones*Apigenin, Luteolin*Celery, fresh parsley, olives, oregano, peppers and rosemarySuppression of oxidative stress via anti-inflammatory effects on NF-kB, brain support, protection and memory increaseFlavanols*Epicatechin-gallates, Procyanidins, Catechin*Tea, grapes, lentils, cocoa, apples with peel on, apricots, cherries, peaches, blackberries, black grapes, strawberries, blueberries and raspberriesAntioxidant, free radicals scavenging properties. Decrease of the hypothalamic inflammation and microglia overactivation. Improve cognitionIsoflavones*Daidzein*Grape seeds, soy productsImprove in adipose inflammation, and insulin resistance. Improve in cognitive functionFlavans*Genistein*SoybeansAntioxidant and neuroprotective activities. Improve in glucose metabolism, and cognitive function.Phytocannabinoids*Cannabidiol*Cannabis sativa plant/supplementsattenuates oxidative stress, anti-inflammatory effects[@bib149]; [@bib44].flavonoid glycoside*Rutin*Buckwheat, apples with skin, asparagus (specially the bottom part), grapefruit, lemons, orange juice, orangesAnti-inflammatory, antioxidant, neuroprotective, nephroprotective, hepatoprotective effects.[@bib167]**Palmitoylethanolamide (PEA)***Fatty acid amide*\
*N-acylethanolamine family*Egg yolk, soy oil, peanut oil, and corn, peas and beans, tomatoes and potatoesAntioxidant Properties, anti-inflammatory, microglia inhibition, neuroprotective effects[@bib109].**Phenolic acids and Polyphenols**[@bib86].**Phenolic acids***Caffeic acid, Ferulic acid*Apples, coffee beans, blueberries, oranges, peaches, potatoes, pearsAntioxidant and anti-inflammatory properties. Improve in cognition and neurodegeneration**Hydroxy-benzoioc acids***Gallic acids, Oleanolic acid*Grape and raspberry grape juice, longan seeds, strawberries, olive oilNF-κB inhibitors, anti-inflammatory properties.[@bib81]; [@bib1];\
[@bib50].**Trihydroxy-stilbenes***Resveratrol*Grape skin, peanuts, red wine, cranberriesAnti-aging, chemo-preventive, anti-carcinogenic, anti-inflammatory and antioxidant effects[@bib15]; [@bib119].**Tannins/Proanthocyanidins***Catechin, Tannic acids*Coffee, cocoa, lentils, peas, walnuts, berries, olives, plums, tea, chickpeas, herbs and spicesAntioxidant properties, neuroprotective effects[@bib62].\
[@bib35].**Diferuloylmethane***Curcumin*Turmeric plantsAnti-inflammatory and antioxidant activities[@bib160].

Another bioactive compound relevant for brain functioning is vitamin D. Vitamin D belongs to the class of fat-soluble vitamins along with vitamin A, E and K. It is considered a steroid hormone, mostly known for its role in calcium metabolism and its ability to increase the absorption of calcium and phosphorus from the intestine ([@bib34]). However, vitamin D exerts many other biological effects including processes involved in brain development and neuronal activity ([@bib46]). Deficiency in vitamin D is considered a risk factor for neuropsychiatric disorders, including PPD, MDD and schizophrenia ([@bib9]; [@bib144]; [@bib163]; [@bib91]). It causes alterations in brain structure and in dopamine and glutamate signaling. Major dietary sources of vitamin D are salmon, shrimp, herring and sardines, egg yolks and mushrooms ([@bib90]). Zinc is an essential trace mineral required for all physiological systems, including neural functioning and proper cellular function, such as DNA replication, transcription, protein synthesis, maintenance of cell membranes, cellular transport, as well as endocrine, immunological and neuronal systems. Zinc is found mainly in red meat, poultry, fish, and dairy. Dysregulation of zinc is associated with reduced immunological functioning, alterations in cognitive performance, gastrointestinal complaints ([@bib20]). Lower zinc levels can be a consequence of inflammation or nutritional deficiencies and it helps to modulate the hyper-glutamatergic state associated with depression ([@bib155]). Approximately 20% of dietary zinc intake is used by intestinal bacteria supporting the major role of a healthy microbiome in brain function ([@bib131]). In addition, zinc modulates PPAR-γ signaling, which is impaired in zinc deficiency ([@bib92]).

5. A natural strategy to potentiate the *PPAR-neurosteroid axis* and improve mood {#sec5}
=================================================================================

Dietary fatty acids have been implicated in immune and inflammatory processes by regulating NFκB and PPAR-α and γ transcription factor pathways ([@bib24]). In rodents, for instance, high-fat diets alter PPAR pathway causing abnormalities in the microbiome that can be reversed by rosiglitazone, a PPAR-γ agonist ([@bib145]). Several natural bioactive compounds act on PPARs, including the tea plant, soybeans, palm oil, ginger, grapes and wine as well as a number of culinary herbs and spices (e.g. *Origanum vulgare, Rosmarinus officinalis, Salvia officinalis, Thymus vulgaris*) (reviewed by [@bib154]). Curcumin has also shown anti-inflammatory and antioxidant effects by increasing PPAR-γ activity ([@bib76]). OEA, which is a natural metabolite of oleic acid, and an endogenous PPAR-α modulator, shows anti-inflammatory activity ([@bib158]). Then, foods rich in oleic acid, such as olive oil, avocado and almond oil can be used as part of the anti-inflammatory dietary patterns. In addition, omega-3 (or n-3) PUFAs and their metabolites are natural ligands for PPAR-γ ([Table 1](#tbl1){ref-type="table"}). PUFAs affect the neuroendocrine-immune axis of depression through their activity on inflammatory responses ([@bib19]; [@bib87]). EPA and DHA supplementation have been shown to decrease levels of key inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-8 ([@bib162]). Recently, a major role in improving symptoms of depression and anxiety in patients or in elevating mood in healthy individuals was shown in populations that were fed with a Mediterranean-based diet, which is rich in fruits, vegetables, olive oil, and legumes and low in saturated fatty acids and processed foods ([@bib128]). Dietary flavonoids found in fruits and vegetables exert anti-inflammatory effects, as well by suppressing microglia activation through the PPAR-γ mediated pathway ([@bib47]; [@bib36]).

Resveratrol, for example, is considered as a natural PPAR ligand ([@bib100]), showed beneficial effects on depression and anxiety treatment by suppression of inflammatory processes exerted by inhibiting the activation of NLRP3 and NFκB in hippocampus ([@bib39]). Resveratrol, which is present at high levels in red grapes, nuts, and pomegranates, exerts metabolic, antioxidant, and anti-inflammatory activities, as well as neuroprotective effects through PPAR-activation ([@bib69]). Similarly, quercetin induced antidepressant-like effect in the unpredictable chronic mild stress animal model of depression and induces antioxidant, anti-inflammatory activities, reduces excitotoxicity and augments 5-HT levels ([@bib67]), linking the role of inflammation to depression. Foods rich in quercetin are capers, goji berries, onions, asparagus, spinach and red grapes. Resveratrol and quercetin are polyphenolic compounds that improve metabolic syndrome by altering PPAR expression ([@bib26]). PEA shows antidepressant effects by binding at its main target, PPAR-α ([@bib38]), and may increase endogenous levels of the endocannabinoids, anandamide (AEA) and 2-arachinoylglycerol (2-AG) and exert anti-inflammatory, analgesic, and neuroprotective properties ([@bib109]). PEA-rich foods are egg yolk, soy oil, peanut oil, corn seeds, legumes, such as peas and beans, and vegetables, such as tomatoes and potatoes (summarized in [Table 1](#tbl1){ref-type="table"}).

Altogether, food rich in micronutrients that have the ability to stimulate PPAR, in addition to exert important anti-inflammatory actions may also induce significant mood-elevating properties, although the underlying mechanisms are not fully understood. We propose that PPAR might work in synergism with stimulation of neurosteroid biosynthesis to exert their beneficial effects by decreasing inflammation and relieving mood symptoms. Intriguingly, PEA-induced PPAR-α activation engages allopregnanolone levels in frontal cortex, hippocampus and amygdala to improve behavioral abnormalities in an animal model of stress-induced mood disorders ([@bib83]; [@bib113]). Previously, Sasso and colleagues (2010, 2012) showed that PEA-induced activation of PPAR-α increases allopregnanolone levels in the rodent spinal cord ([@bib129], [@bib130]). Moreover, allopregnanolone is also involved in BDNF expression and neurogenesis. In socially isolated mice reduced levels of allopregnanolone in corticolimbic areas are associated with BDNF deficiency, reduced neurogenesis and depressive- and anxiety-like behavior, supporting a multifunctional role of allopregnanolone for depression and anxiety prevention ([@bib101]; [@bib45]; [@bib14]; [@bib7]). Intriguingly, studies have suggested that PPAR-α activation by administering synthetic PPAR-α agonists, including fenofibrate, is associated with stimulation of BDNF signaling cascade and improvement of behavioral dysfunction ([@bib63]). These findings suggest that PPAR-α regulation may represent a suitable target for developing new strategies for the treatment of neuropsychiatric disorders characterized by deficiency in neurosteroidogenesis, including MDD, PTSD and PPD ([@bib148]; [@bib125]; [@bib121], [@bib122]; [@bib110]; [@bib165]; [@bib95]). Moreover, FDA-approved synthetic PPAR-α agonists, including the fibrates (e.g., fenofibrate, clofibrate), prescribed for the treatment of hypercholesterolemia, could be repurposed to treat mood disorders by targeting the *PPAR-allopregnanolone* *axis* (discussed in [@bib113]).

These summaries are in support of a PPAR role both as a mediator of neuroinflammation during neuropathophysiological conditions and as a suitable pharmacological target to develop novel therapeutic approaches to treat mood disorders by designing functional diets that mediate upregulation of neurosteroid biosynthesis.

6. Conclusion {#sec6}
=============

The nuclear receptors, PPAR-α and γ appear as novel fascinating targets for the treatment of mood disorders caused by stressful conditions, such as during mood instability and low-grade inflammatory states that occur during pregnancy or after birth. This review focuses on the role of neuroinflammation as a molecular mechanism underlying mood disorders, including perinatal depression and highlights the potential impact of PPAR regulation in these processes. We addressed the possibility that by downregulating inflammatory processes, following activation of PPAR with a healthy diet rich in PPAR-bioactive micronutrients found in functional foods, may help preventing, managing and treating mood disorders. These ligands by stimulating anti-inflammatory mechanisms and, possibly, by enhancing neurosteroid biosynthesis, may provide a future, more natural and safe approach to prevent and alleviate pathophysiological processes that lead to perinatal depression and other mood disorders.

CRediT authorship contribution statement {#sec8}
========================================

**Francesco Matrisciano:** Writing - original draft. **Graziano Pinna:** Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Visualization, Writing - original draft, Writing - review & editing.

This study was supported by the 10.13039/100000005United States Department of Defense Grant W81XWH-15-1-0521 to GP.
